{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:18:55Z","timestamp":1760908735744},"reference-count":20,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T00:00:00Z","timestamp":1574380800000},"content-version":"vor","delay-in-days":2761,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1093\/annonc\/mdr385","type":"journal-article","created":{"date-parts":[[2011,9,18]],"date-time":"2011-09-18T00:23:33Z","timestamp":1316305413000},"page":"1254-1259","source":"Crossref","is-referenced-by-count":17,"title":["Two escalated followed by six standard BEACOPP in advanced-stage high-risk classical Hodgkin lymphoma: high cure rates but increased risk of aseptic osteonecrosis"],"prefix":"10.1016","volume":"23","author":[{"given":"A.","family":"Foss\u00e5","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.H.","family":"Fiskvik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Kolstad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.F.","family":"Lauritzsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Aurlien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.K.","family":"Blystad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.H.","family":"Hole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.M.","family":"Ikonomou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Holte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdr385_bb0010","doi-asserted-by":"crossref","first-page":"6400","DOI":"10.1200\/JCO.2005.05.016","article-title":"State-of-the-art therapeutics: Hodgkin\u2019s lymphoma","volume":"23","author":"Connors","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr385_bb0015","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/asheducation-2009.1.497","article-title":"Standard therapy of advanced Hodgkin lymphoma","author":"Kuruvilla","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1093\/annonc\/mdr385_bb0020","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1080\/07357900600981380","article-title":"Could BEACOPP be the new standard for the treatment of advanced Hodgkin\u2019s lymphoma (HL)?","volume":"24","author":"Diehl","year":"2006","journal-title":"Cancer Invest"},{"key":"10.1093\/annonc\/mdr385_bb0025","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa022473","article-title":"Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin\u2019s disease","volume":"348","author":"Diehl","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdr385_bb0030","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2008.19.8820","article-title":"Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin\u2019s lymphoma: 10 years of follow-up of the GHSG HD9 study","volume":"27","author":"Engert","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr385_bb0035","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1200\/JCO.2008.17.0910","article-title":"ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin\u2019s lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr385_bb0040","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A prognostic score for advanced Hodgkin\u2019s disease. International Prognostic Factors Project on Advanced Hodgkin\u2019s Disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdr385_bb0045","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1093\/jnci\/djq188","article-title":"Eleventh biannual report of the Cochrane Haematological Malignancies Group: focus on Hodgkin lymphoma","volume":"102","author":"Bauer","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdr385_bb0050","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1182\/blood-2006-04-019901","article-title":"Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome","volume":"109","author":"Dann","year":"2007","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdr385_bb0055","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1023\/A:1008301225839","article-title":"Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin\u2019s disease. German Hodgkin\u2019s Lymphoma Study Group (GHSG)","volume":"11","author":"Engel","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdr385_bb0060","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.2682.2682","article-title":"Secondary MDS\/AML in Hodgkin`s lymphoma patients treated within German Hodgkin Study Group (GHSG) clinical trials after introduction of the BEACOPP protocol","volume":"116","author":"Eichenauer","year":"2010","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdr385_bb0065","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1093\/annonc\/mdn376","article-title":"Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials","volume":"19","author":"Sieniawski","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdr385_bb0070","doi-asserted-by":"crossref","first-page":"7555","DOI":"10.1200\/JCO.2005.08.138","article-title":"Secondary amenorrhea after Hodgkin\u2019s lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin\u2019s Lymphoma Study Group","volume":"23","author":"Behringer","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr385_bb0075","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1200\/JCO.1989.7.11.1630","article-title":"Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin\u2019s disease: Cotswolds meeting","volume":"7","author":"Lister","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr385_bb0080","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1080\/10428190600688313","article-title":"Multicentre phase II study of the baseline BEACOPP regimen for patients with advanced-stage Hodgkin\u2019s lymphoma","volume":"47","author":"Niitsu","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdr385_bb0085","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1200\/JCO.2003.06.028","article-title":"14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin\u2019s lymphoma: results of a pilot study of the German Hodgkin\u2019s Lymphoma Study Group","volume":"21","author":"Sieber","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr385_bb0090","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.8544","volume":"27","author":"Diehl","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr385_bb0095","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.autrev.2010.06.007","article-title":"Steroid induced osteonecrosis: an analysis of steroid dosing risk","volume":"9","author":"Powell","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1093\/annonc\/mdr385_bb0100","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0009-9260(97)80253-X","article-title":"Avascular necrosis of bone following an intensified chemotherapy regimen including high dose steroids","volume":"52","author":"Thornton","year":"1997","journal-title":"Clin Radiol"},{"key":"10.1093\/annonc\/mdr385_bb0105","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2257.1994.tb00381.x","article-title":"Osteonecrosis following treatment for Hodgkin\u2019s disease","volume":"16","author":"Ellis","year":"1994","journal-title":"Clin Lab Haematol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419346800?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419346800?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/23\/5\/1254\/478894\/mdr385.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T09:17:27Z","timestamp":1624439847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419346800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S0923753419346800"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdr385","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}